Review of serious adverse events following yellow fever vaccination
New recommendations for clinical practice with strengthened measures to minimise the risk of serious and fatal reactions post vaccination are published
On 21 November 2019, the Medicines and Healthcare Regulatory Agency (MHRA), Public Health England (PHE), the National Travel Health Network and Centre and Health Protection Scotland (HPS) circulated a joint letter to inform health professionals of the recommendations of a Commission on Human Medicines (CHM) review of serious and fatal reactions following administration of yellow fever vaccine. The CHM found the balance between benefits and risks of yellow fever vaccine remains favourable for most travellers when used as indicated, but updated its recommendations to minimise risks to vaccinees. The recommendations aim to strengthen measures to minimise risk in those with weakened immune systems, for those aged 60 years or older, and anyone who has had their thymus removed to ensure that only those at significant and unavoidable risk of yellow fever are offered the vaccine.
The letter contains specific recommendations, and is available from this link. It will also be disseminated through alternative resources.
Yellow Fever Vaccination Centres will receive a direct email from NaTHNaC on this issue.
NaTHNaC will update their clinical resources in due course.
Explore more
Middle East respiratory syndrome coronavirus (MERS-CoV) reminder
NaTHNaC has reviewed MERS-CoV advice for UK travellers in line with current UK Health Security Agency recommendations and is reminding travellers to b
Updated: 05 September 2024Updated cholera 'green book' chapter published
The cholera chapter in the 'green book' (Immunisation against infectious disease) has been updated
Updated: 30 August 2024Crimean-Congo haemorrhagic fever in Spain
Advice for travellers following confirmed cases of CCHF in Spain
Updated: 28 August 2024Worldwide rabies risk reminder
A reminder for travellers of the global risk of rabies
Updated: 25 July 2024